Skip to main content
. 2021 Oct 23;13(21):5322. doi: 10.3390/cancers13215322

Figure 1.

Figure 1

Determining appropriate concentrations of 17-β-Estradiol (E2)or Fulvestrant (FUL) treatment in MCF-7 breast cancer cells. (a) MTT cell viability assay proceeded to evaluate cytotoxic responses against two different concentrations of each drug. Columns represent the mean ± Std.dev of three independent experiments with at least four repeats. The analysis was performed by one-way ANOVA, Tukey’s multiple comparison test. (b) Viable cell numbers of MCF-7 cells treated with 100 nM and 1000 nM 17-β-Estradiol (E2), and 100 nM and 500 nM Fulvestrant (FUL) (**** p < 0.0001 by two-way ANOVA, Tukey’s multiple comparison test). (c) Representative image of colony formation assay to compare untreated control samples to 17-β-Estradiol (E2) (100–1000 nM) or Fulvestrant (FUL) (100–500 nM); (d) confirmation assay to evaluate E2 and FUL treatment by immunoblotting of dose-dependent E2 or FUL treated MCF-7 cell lysates. β-tubulin was used as a loading control. The relative densitometry analysis was performed by two-way ANOVA Tukey’s multiple comparison test (**** p < 0.0001, uncropped Western Blot Figures are shown in Figure S1).